Scynexis Inc

This advisory proposal asks stockholders to approve, on a non-binding basis, the overall compensation of SCYNEXIS’s named executive officers as disclosed under Item 402 of Regulation S-K. Management frames executive pay as aligned with stockholder interests through an emphasis on equity over cash and ties annual incentive outcomes to corporate and individual performance metrics. The Compensation Committee uses market benchmarking and an independent consultant (Pearl Meyer) to set pay levels and plan structures, and it believes the programs appropriately motivate and retain key employees in a competitive biotech labor market. A vote in favor provides the Board and Compensation Committee with validation of the current compensation approach and will be considered when making future compensation decisions, although the advisory nature means the Board retains discretion to modify pay practices. Key contextual factors include the Company's stage (clinical-stage biotech), historical use of equity as a central retention tool, and recent sizable equity grants to executives, which drive long-term alignment but also contribute to dilution. Potential shareholder concerns include the absolute levels of realized pay in years with significant equity vesting or option exercises and the balance between cash and equity pay given the Company's financial position. The Company discloses severance and change-in-control protections for executives; while these are standard for the industry, investors will assess whether these provisions are proportionate given Company size. Because the vote is non-binding, a majority 'For' supports management’s strategy, while a 'Against' would signal investor dissatisfaction and likely trigger engagement and potential changes to the pay framework. Overall, the Board recommends 'For' believing the pay programs appropriately incentivize management to deliver clinical and corporate milestones while aligning with long-term shareholder value creation.

This non-binding proposal asks shareholders to indicate whether future non-binding advisory votes on executive compensation should occur annually, biennially, or triennially. Management and the Compensation Committee advocate for annual votes, arguing that yearly say-on-pay is the most effective way to obtain regular feedback on compensation decisions and to maintain ongoing shareholder engagement—particularly important for a clinical-stage biotech where developments and milestone-driven compensation decisions can occur frequently. An annual frequency increases cadence for investor communication and can be used by the Board to adjust compensation practices responsive to shareholder sentiment; however, it also increases administrative cycles and may result in repetitive votes where compensation frameworks do not materially change year-to-year. A two- or three-year frequency can reduce vote fatigue and administrative burden and provide a longer horizon for multi-year performance plans, but may delay shareholder feedback on material compensation changes. Given SCYNEXIS’s reliance on equity incentive grants and periodic milestone-based outcomes, management’s preference for annual votes is defensible to ensure timely investor input on compensation alignment. The advisory nature means the Board can consider shareholder preference but is not bound to implement it; a majority for a different cadence would be treated as guidance. Investors will weigh the tradeoff between timely oversight (annual) and efficiency and longer performance measurement periods (biennial or triennial) when casting their votes. The Board recommends 'One Year' to preserve frequent engagement and to ensure compensation decisions remain aligned with shareholder expectations in a dynamic development environment.

This management proposal requests shareholder approval to expand the share reserve of the 2024 Equity Incentive Plan by 9.6 million shares to permit continued grants of options, RSUs, performance awards and other equity instruments used for employee and director compensation. Management justifies the request by citing the need to attract and retain talent in the competitive biotech sector, historical burn rates (roughly 4–6% in recent years) and a current available run-rate expected to last one to two years absent an increase. The company emphasizes plan features intended to protect stockholders — no single-trigger change-in-control vesting acceleration, a prohibition on repricing without shareholder approval, prohibition on share recycling, no discounted options, and limits on dividend equivalents on unvested awards — to mitigate dilution and governance concerns. The proposal will increase the plan’s authorized pool to a stated total and, if approved, yield an estimated post-meeting available reserve (management’s estimate: 11,908,196 shares available after the meeting based on April 1, 2026 figures). Critics will focus on dilution risk, overhang and the effect on EPS and voting power, and will scrutinize grant practices, performance conditions and CEO/NEO grant sizes. The board’s recommendation and disclosure of benchmarking work with an independent consultant (Pearl Meyer) and the stated reasonable size of the request aim to persuade investors that the increment is prudent and calibrated to hiring and retention needs. A rejection would constrain the Company’s ability to grant competitive awards, potentially undermining recruitment and retention and affecting future corporate transactions. Given the company’s current reliance on equity and its disclosure of governance safeguards, the proposal represents a trade-off between near-term dilution and longer-term talent alignment and value-creation expectations.

This management proposal seeks stockholder approval to increase authorized common shares significantly to provide the company flexibility to effect financings, accommodate warrant exercises from a recent private placement, and support other corporate needs; the proposal offers two alternative authorized-share totals depending on whether the previously proposed reverse stock split is approved and implemented. The board frames the increase as necessary to reserve shares for potential issuance (including for exercisable warrants from a March 30, 2026 private placement) and to enable timely capital-raising and transactional agility without the delay and cost of recurrent special meetings. The conditional option (60 million if a reverse split is implemented, otherwise 300 million) reflects the board’s attempt to align authorized share counts with post-split share capital structures and to avoid insufficiency of authorized shares after corporate actions. Investors should weigh the dilution risk and potential anti-takeover optics — the company discloses that newly authorized shares would be issuable for general corporate purposes and could dilute existing holders — against the operational necessity to ensure shares are available for financing, strategic transactions, equity plans and warrant exercises. The board discloses the specifics of the private placement and the number of outstanding instruments that consume authorization, which helps quantify near-term needs, but shareholders may remain concerned about the scale of potential future issuances absent explicit pre-commitments. The company notes it could abandon the amendment at its discretion if circumstances change, and the amendment does not change rights of existing common shares other than dilutionary effects if issued. Approval would facilitate closing and monetizing the private placement proceeds if warranted, while rejection would require repeated stockholder votes and could jeopardize exercise of certain instruments or timely financings. Overall, the proposal trades potential dilution and governance concerns for financing flexibility and operational certainty in executing near-term capital and strategic plans.